Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 27,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 13, 2025 20:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086167 · ownership.xml · derivative · entry 1 Atkins Michael B. · CIK 0002004793 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| May 24, 2024 Filed May 24, 2024 23:48 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 6,723 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0000950170-24-064843 · ownership.xml · derivative · entry 1 Atkins Michael B. · CIK 0002004793 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,723 Underlying: Common Stock · 6,723 shares Expires 2034-05-23 F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 00:19 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000950170-24-002214 · ownership.xml · derivative · entry 1 Atkins Michael B. · CIK 0002004793 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The option was granted on January 4, 2024. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.